Perspective Therapeutics (NYSE:CATX) Shares Gap Up – Should You Buy?

Perspective Therapeutics, Inc. (NYSE:CATX)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $11.69, but opened at $12.28. Perspective Therapeutics shares last traded at $11.93, with a volume of 14,121 shares trading hands.

Analysts Set New Price Targets

CATX has been the topic of a number of research reports. Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of Perspective Therapeutics in a report on Thursday. UBS Group started coverage on Perspective Therapeutics in a research note on Thursday. They issued a “buy” rating and a $20.00 target price on the stock. Bank of America began coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 price target for the company. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, Oppenheimer restated an “outperform” rating and set a $22.00 price objective on shares of Perspective Therapeutics in a research report on Friday, October 11th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $20.63.

Perspective Therapeutics Trading Down 2.9 %

The company has a 50-day simple moving average of $13.76.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. On average, analysts forecast that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Perspective Therapeutics in the 1st quarter worth about $15,511,000. Affinity Asset Advisors LLC acquired a new stake in Perspective Therapeutics in the 1st quarter valued at about $6,069,000. Nicholson Wealth Management Group LLC purchased a new position in Perspective Therapeutics during the 3rd quarter valued at about $21,390,000. Finally, Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics during the second quarter worth about $3,951,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.